First-in-human findings provide encouraging safety and pharmacokinetic evidence supporting the Sagitta^® targeted drug delivery platform family.

PDC Therapeutics is highlighting new clinical results from RS-0139, developed by RS Research using its proprietary Sagitta^® targeted drug delivery platform family. The findings were presented at ESMO Congress 2026 in Madrid (1095eP), marking the first detailed disclosure of the Phase 1a/1b study in 16 heavily pretreated patients with advanced solid tumors.

At 40-60 mg/m², no neutropenia of any grade was observed among 11 patients, without G-CSF support. The maximum tolerated dose was 75 mg/m², and adverse events, including dose-limiting toxicities, were observed across dose levels, as detailed in the ePoster. Pharmacokinetic analyses showed that released docetaxel represented approximately 4% of total measured docetaxel, with no accumulation across repeated three-week dosing cycles. Exploratory analyses also identified CA-125 reductions exceeding 80% in two patients with gynecological cancers.

These early findings provide clinical evidence consistent with Sagitta^®‘s intended delivery approach and support further investigation of RS-0139. As preparations advance for an international Phase 2 program, the milestone also strengthens the scientific foundation for future platform development and co-development opportunities.

RS-0139 is an investigational medicine and has not been approved by any regulatory authority.